Can open-source R&D reinvigorate drug research?

Nature reviews. Drug discovery ·Vol. 5 ·No. 9 ·2006-09-00 ·Pages 723-9

Munos B

Abstract

The low number of novel therapeutics approved by the US FDA in recent years continues to cause great concern about productivity and declining innovation. Can open-source drug research and development, using principles pioneered by the highly successful open-source software movement, help revive the industry?

MeSH Terms

Clinical Trials as Topic/methods Databases, Factual Drug Approval/methods Drug Design Humans Organizational Innovation Research/organization & administration,trends Research Design Software Technology, Pharmaceutical/methods,trends

Authors & Affiliations

1 authors, click to expand affiliations / ORCID

Munos Bernard

Bernard Munos is at Eli Lilly & Co., Lilly Corporate Center, 1085, Indianapolis, Indiana 46285, USA. bhmunos@stanfordalumni.org

Article Info

Journal

Nature reviews. Drug discovery

Abbr.

Nat Rev Drug Discov

ISSN

1474-1776

DOI

10.1038/nrd2131

bhmunos@stanfordalumni.org

Published

2006-09-00

Epub

2006-00-18

Pages

723-9

Language

English

Region

England

NLM ID

101124171

Subset

External Links

PubMed source DOI: 10.1038/nrd2131 View journal details

Analysis Services

Can open-source R&D reinvigorate drug research?

Contact

WeChat Official Account